January 2021 Issue Table Of Contents

From The Editor

• New Year, New President, New Outlook

Feature Articles

• Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In
• How A First-Time Pharma CEO Faces Hypergrowth

Capitol Perspectives

• Most Favored Nation Regulation Could Upend The Rx Market

CEO Corner

• Benefits Of Beantown Biotech And Lessons For Life Science Leaders

Companies To Watch

• Artax Biopharma

From Policy to Execution

• Restoring Public Health And The Economy To Normalcy

Industry Research

• Sponsor Interest In Current Phase 1 Trends

Inside The Industry

• Going Public In Mid-Pandemic
• 5 Elements Of A Long-Term Partnership Strategy
• China’s Proposed IP Law Changes May Drive Pharma Innovation
• Transforming Your Organizational Mindset On Quality Compliance
• Increasing Patient Diversity In Clinical Trials
• Emerging Trends For Life Sciences IPOs During The Pandemic

Industry Leader

• What I Learned Running A Biotech During The Pandemic

Leadership Lessons

• Leadership And Strategic Teams –3 Keys To Development

Ask The Board

• Could The Pandemic Be Just What The Doctor Ordered For Bringing More R&D Minds To Major Biopharma Hubs (e.g., Boston, San Fran)?
• What COVID-19-Induced Trends Impacting Your Company’s Operations Do You Anticipate Continuing Well Beyond The End Of The Current Pandemic?
• What Happens If We Have A Bunch Of COVID-19 Therapeutic And Vaccine Development Failures? Could Biopharma Be The Next Dot-Com Bubble To Burst In 2021?